Pharmacology

Bisphosphonates and Gastrointestinal Cancer: Is There a Link?

Preclinical studies have shown that bisphosphonates, one of the treatments for osteoporosis, have antitumor properties, but other studies have sounded a warning about esophageal cancer. To find out whether adverse effects on the gastrointestinal (GI) tract, such as mucosal irritation, could lead to ulceration and possibly cancer, researchers from University Park in Nottingham, United Kingdom, designed a series of nested case-control studies using the 2 largest population databases in the United Kingdom. They matched patients aged ≥ 50 years who had a diagnosis of primary GI cancer with up to 5 controls.


 

Recommended Reading

Oncologist Communication Feedback Improves Patient Trust
Federal Practitioner
A Brighter Prognosis in Nonalcoholic Fatty Liver Disease
Federal Practitioner
Posterior Reversible Encephalopathy Syndrome as a Complication of Chemotherapy
Federal Practitioner
CLEOPATRA Study and MBC
Federal Practitioner
Diabetes May Increase Risk of Cancer Death
Federal Practitioner
Clinical Trial List for Cancer
Federal Practitioner
Burn Scar Carcinoma: Patients With Marjolin's Ulcer
Federal Practitioner
Evaluation of Vitamin D Supplementation in a Veteran Population
Federal Practitioner
Vitamin D Deficiency
Federal Practitioner
Venous Thromboembolism and Weight Changes in Veteran Patients Using Megestrol Acetate as an Appetite Stimulant
Federal Practitioner